Difference between revisions of "Part:BBa K1781002"
(Add a) |
(Add an improvement to this part) |
||
Line 6: | Line 6: | ||
==Improvement and New Application for ZHER2== | ==Improvement and New Application for ZHER2== | ||
− | <b>Group:</b> iGEM2021_Greatbay_SCIE | + | <b>Group:</b> iGEM2021_Greatbay_SCIE <br> |
<b>Author:</b> iGEM2021_Greatbay_SCIE | <b>Author:</b> iGEM2021_Greatbay_SCIE | ||
Revision as of 05:12, 20 October 2021
ZHER2 - affibody with affinity to cytoplasmic domain of HER2
ZHER2 was one of the first affibodies created and it binds to the Human Epidermal Growth Factor 2 (HER2). They originate from mutations in the Immunoglobin G Binding Domain of Protein A from Staphylococcus aureus. Affibodies are engineered to bind to larger proteins or peptides where they imitate monoclonal antibodies. They are used in a multitude of therapies in biotechnology to bioimaging. ZHER2 can particular be used as a protein-protein interaction tool, as well as a way to verify antibody interactions as it binds to the cytoplasmic domain of HER2 at a different epitope than the antibodies.
Improvement and New Application for ZHER2
Group: iGEM2021_Greatbay_SCIE
Author: iGEM2021_Greatbay_SCIE
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 4
Illegal AgeI site found at 220 - 1000COMPATIBLE WITH RFC[1000]